Whether Anagrelide has been officially launched in the country and the relevant approval progress

Anagrelide (Anagrelide) is a drug used to treat essential thrombocythemia (ET) and other types of hyperthrombocytemia. Currently, the drug has not yet been officially launched on the Chinese mainland market. According to public information, anagrelide is still in the clinical trial or marketing application stage. The specific launch time is subject to the final approval results of the National Food and Drug Administration (NMPA). It is expected that it may take 1-3 years or more.

While waiting for anagrelide to be launched in China, patients can choose other marketed treatment options, such as hydroxyurea, interferon, etc., through doctor evaluation, or participate in clinical trials of anagrelide (if any). All treatment plans must be strictly followed as prescribed by the doctor, and self-medication is not allowed.

Currently, domestically produced anagrelide is available on the domestic market, but it has not yet been included in medical insurance. The price is approximately 7,000 yuan per box. The specific price may vary depending on the region and sales channel. Patients are advised to consult at the local hospital pharmacy.

In overseas markets, the price of the original drug anagrelide is relatively low. For example, the price of the European version of the original drug is about 3,000 multiple RMB per box. In addition, the price of generic drugs produced in Laos is more affordable, with each box selling for about a few hundred yuan. It should be noted that the specific prices of overseas drugs may change due to factors such as exchange rate fluctuations, tariffs, and transportation costs, so the above prices are for reference only.

Reference link:https://www.drugs.com